Jay R. Luly
2017
In 2017, Jay R. Luly earned a total compensation of $4.3M as President and Chief Executive Officer at Enanta Pharmaceuticals, a 24% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $345,648 |
---|---|
Option Awards | $2,055,720 |
Salary | $581,203 |
Stock Awards | $1,279,980 |
Other | $18,551 |
Total | $4,281,102 |
Luly received $2.1M in option awards, accounting for 48% of the total pay in 2017.
Luly also received $345.6K in non-equity incentive plan, $581.2K in salary, $1.3M in stock awards and $18.6K in other compensation.
Rankings
In 2017, Jay R. Luly's compensation ranked 2,341st out of 14,666 executives tracked by ExecPay. In other words, Luly earned more than 84.0% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 2,341 | 84th |
Manufacturing | 822 | 86th |
Chemicals And Allied Products | 216 | 90th |
Drugs | 165 | 91st |
Pharmaceutical Preparations | 130 | 90th |
Luly's colleagues
We found four more compensation records of executives who worked with Jay R. Luly at Enanta Pharmaceuticals in 2017.
News
Enanta Pharmaceuticals CEO Jay Luly's 2022 pay jumps 37% to $7.3M
January 20, 2023
Enanta Pharmaceuticals CEO Jay Luly's 2021 pay rises 2% to $5.3M
January 21, 2022
Enanta Pharmaceuticals CEO Jay Luly's 2020 pay rises 16% to $5.2M
January 21, 2021
Enanta Pharmaceuticals CEO Jay Luly's 2019 pay slips 1% to $4.5M
January 17, 2020
Enanta Pharmaceuticals CEO Jay Luly's 2018 pay rises 5% to $4.5M
January 18, 2019